Apr 18, 2023 / 12:45PM GMT
Gil Blum - Needham & Company, LLC - Analyst
Good morning, everyone, and thank you for joining us this morning at the Needham & Company conference. My name is Gil Blum and I'm a senior biotech analyst here at Needham & Company covering the gene therapy space.
It is my pleasure to have with me today Dr. Gaurav Shah, Rocket Pharma's CEO. (Conference Instructions)
Questions and Answers:
Gil Blum - Needham & Company, LLC - AnalystSo maybe it's a good place to start as an introduction. I mean, investors have become kind of sanguine on gene therapy as of late. So do you think that potential for larger population drug approvals -- there is a filing for SRP-9001 in DMD and Exa-Cel in SCT, and your own drug in Danon disease. Do you think that could change sentiment?
Gaurav Shah - Rocket Pharmaceuticals, Inc. - CEO
Good to see you again. Thanks for having us this year. I think it will potentially change sentiment. I think there was a time when gene therapy was a platform that was very exciting,
Trustpilot
